Table 1.
Univariable analysis of the demographics and baseline characteristics of 152 RA patients
| Remission in depression (Group A) | No remission in depression (Group B) | |||
|---|---|---|---|---|
| n | 124 | 28 | ||
| Age (years) | 53 (42–65) | 63 (57–73) | 0.000* | |
| Sex (female), n (%) | 107 (86.3) | 19 (67.9) | 0.039** | |
| Body mass index (kg/m2) | 21.0 (19.8–23.8) | 21.1 (19.6–24.3) | 0.69* | |
| Bio-naive (%) | 69.4 | 75.0 | 0.37** | |
| Disease duration (years) | 3.9 (1.3–9.4) | 4.1 (2.0–10.8) | 0.66* | |
| Prednisolone dosage (mg/d) | 2.5 (0–5.0) | 4.0 (0.75–5.0) | 0.095* | |
| MTX dosage (mg/w) | 8 (6–10) | 8 (4–10) | 0.14* | |
| bDMARDs | Infliximab | 46 | 9 | 0.126** |
| Etanercept | 16 | 2 | ||
| Adalimumab | 16 | 7 | ||
| Golimumab | 8 | 2 | ||
| Certolizumab Pegol | 8 | 0 | ||
| Tocilizumab | 23 | 3 | ||
| Abatacept | 7 | 5 | ||
| ESR (mm/H) | 29 (14–53) | 39 (20–60) | 0.27* | |
| CRP (mg/dL) | 1.2 (0.33–3.6) | 2.3 (0.40–5.3) | 0.33* | |
| MMP3 (ng/mL) | 147.0 (74.1–312.0) | 225.0 (164.2–311.1) | 0.021* | |
| SDAI | 21.5 (13.4–30.0) | 26.9 (23.1–34.8) | 0.058* | |
| HAQ-DI | 0.375 (0–0.75) | 0.8125 (0.25–1.375) | 0.015* | |
| HAM-D score | before treatment | 4 (2–7) | 9 (5.75–12.5) | 0.001* |
| HAM-D ≥8 (%) | 28 (22.6) | 17 (60.7) | 0.000** | |
| after treatment | 2 (0–4) | 10 (8–12.25) | 0.001* | |
| HAM-D ≥8 (%) | 0 (0) | 28 (100) | 0.000** | |
| SF-36 | PCS | 30.1 (18.9–39.1) | 22.2 (11.5–32.9) | 0.26* |
| MCS | 50.8 (43.9–56.2) | 46.4 (42.1–53.0) | 0.26* | |
| RCS | 46.5 (33.7–57.1) | 34.6(20.7–43.3) | 0.009* |
MTX: methotrexate; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; MMP3: matrix metalloproteinase 3; SDAI: simplified disease activity index; HAQ-DI: health assessment questionnaire disability index; HAM-D: Hamilton Depression Rating Scale; SF-36: short form-36; PCS: physical component summary score; MCS: mental component summary score; RCS: role/social component summary score
*
analysis using Mann-Whitney U test
**
analysis using chi-squared test for independence